Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

ABSTRACT: The objective was to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) in treating adults with COVID-19 at high-risk of developing severe COVID-19 who do not require supplemental oxygen, compared to no treatment, from the Spanish National Health System (NHS) perspective. A decision-tree for the first year followed by a two-state Markov model with annual cycles for a lifetime horizon was developed. A cohort of 1000 high-risk, symptomatic COVID-19 patients entered the decision-tree for each comparator, divided into hospitalized patients, considering their level of care, and outpatients, for whom only symptom duration was considered. Vaccination status of patients and COVID-19-specific mortality for hospitalized patients were considered. NMV/r efficacy in reducing hospitalizat

SUBMITTER: Azanza JR 

PROVIDER: S-EPMC11892420 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature